| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
2,630,000,000 |
| Market
Cap: |
405.76(B) |
| Last
Volume: |
7,590,777 |
Avg
Vol: |
8,309,807 |
| 52
Week Range: |
$144.45 - $174.48 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
DOW JONES COMPOSITE |
| |
DOW JONES INDUSTRIAL AVERAGE |
|
NYSE COMPOSITE |
| |
S&P 100 |
|
S&P 500 |
| |
MAJOR MARKET |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 21 |
| Guru Rank Value : 20.3 |
| Guru Occurances : 6 |
|
|
|
|
|
| |
|
Company Profile Johnson & Johnson is a holding company. Through its subsidiaries, Co. is engaged in the research and development, manufacture and sale of products in the health care field. Co. has three business segments: Consumer Health, which includes products focused on personal healthcare used in the skin health/beauty, over-the-counter medicines, baby care, oral care, women's health and wound care markets; Pharmaceutical, which is focused on six therapeutic areas: Immunology, Infectious Diseases, Neuroscience, Oncology, Cardiovascular and Metabolism and Pulmonary Hypertension; and Medical Devices, which includes products used in the Interventional Solutions, Orthopaedics, Surgery, and Vision fields.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
8,891 |
68,288 |
115,451 |
522,170 |
| Total Sell Value |
$1,441,765 |
$10,723,734 |
$18,652,688 |
$88,845,171 |
| Total People Sold |
1 |
2 |
5 |
10 |
| Total Sell Transactions |
1 |
2 |
5 |
24 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Wengel Kathryn E |
EVP, Chief GSC Officer |
• • – |
2019-02-11 |
4 |
D |
$131.94 |
$533,961 |
D/D |
(4,047) |
41,601 |
|
- |
|
| Wengel Kathryn E |
EVP, Chief GSC Officer |
• • – |
2019-02-11 |
4 |
A |
$0.00 |
$0 |
D/D |
1,102 |
45,648 |
|
- |
|
| Wengel Kathryn E |
EVP, Chief GSC Officer |
• • – |
2019-02-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,722 |
44,546 |
|
- |
|
| Taubert Jennifer L |
EVP, WW Chair, Pharmaceuticals |
• • – |
2019-02-11 |
4 |
D |
$131.94 |
$822,778 |
D/D |
(6,236) |
73,751 |
|
- |
|
| Taubert Jennifer L |
EVP, WW Chair, Pharmaceuticals |
• • – |
2019-02-11 |
4 |
A |
$0.00 |
$0 |
D/D |
1,599 |
79,987 |
|
- |
|
| Taubert Jennifer L |
EVP, WW Chair, Pharmaceuticals |
• • – |
2019-02-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,748 |
78,388 |
|
- |
|
| Mesquita Jorge S. |
Exec VP, WW Chair, Consumer |
• • – |
2019-02-11 |
4 |
D |
$131.94 |
$1,527,469 |
D/D |
(11,577) |
27,344 |
|
- |
|
| Mesquita Jorge S. |
Exec VP, WW Chair, Consumer |
• • – |
2019-02-11 |
4 |
A |
$0.00 |
$0 |
D/D |
2,783 |
38,921 |
|
- |
|
| Mesquita Jorge S. |
Exec VP, WW Chair, Consumer |
• • – |
2019-02-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,968 |
36,138 |
|
- |
|
| Stoffels Paulus |
Vice Chair, Exec Committee |
• • – |
2019-02-11 |
4 |
D |
$131.94 |
$2,095,735 |
D/D |
(15,884) |
231,516 |
|
- |
|
| Stoffels Paulus |
Vice Chair, Exec Committee |
• • – |
2019-02-11 |
4 |
A |
$0.00 |
$0 |
D/D |
5,154 |
247,400 |
|
- |
|
| Stoffels Paulus |
Vice Chair, Exec Committee |
• • – |
2019-02-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
31,428 |
242,246 |
|
- |
|
| Sneed Michael E |
EVP, Global Corp Aff & COO |
• • – |
2019-02-11 |
4 |
D |
$131.94 |
$461,394 |
D/D |
(3,497) |
49,383 |
|
- |
|
| Sneed Michael E |
EVP, Global Corp Aff & COO |
• • – |
2019-02-11 |
4 |
A |
$0.00 |
$0 |
D/D |
1,193 |
52,880 |
|
- |
|
| Sneed Michael E |
EVP, Global Corp Aff & COO |
• • – |
2019-02-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,275 |
51,687 |
|
- |
|
| Fasolo Peter |
Exec VP, Chief HR Officer |
• • – |
2019-02-11 |
4 |
D |
$131.94 |
$1,014,223 |
D/D |
(7,687) |
88,328 |
|
- |
|
| Fasolo Peter |
Exec VP, Chief HR Officer |
• • – |
2019-02-11 |
4 |
A |
$0.00 |
$0 |
D/D |
2,068 |
96,015 |
|
- |
|
| Fasolo Peter |
Exec VP, Chief HR Officer |
• • – |
2019-02-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,609 |
93,947 |
|
- |
|
| Ullmann Michael H |
Exec VP, General Counsel |
• • – |
2019-02-11 |
4 |
D |
$131.94 |
$1,075,443 |
D/D |
(8,151) |
133,460 |
|
- |
|
| Ullmann Michael H |
Exec VP, General Counsel |
• • – |
2019-02-11 |
4 |
A |
$0.00 |
$0 |
D/D |
2,177 |
141,611 |
|
- |
|
| Ullmann Michael H |
Exec VP, General Counsel |
• • – |
2019-02-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,273 |
139,434 |
|
- |
|
| Gorsky Alex |
Chairman, CEO |
• • – |
2019-02-11 |
4 |
D |
$131.94 |
$4,931,126 |
D/D |
(37,374) |
389,456 |
|
- |
|
| Gorsky Alex |
Chairman, CEO |
• • – |
2019-02-11 |
4 |
A |
$0.00 |
$0 |
D/D |
12,127 |
426,830 |
|
- |
|
| Gorsky Alex |
Chairman, CEO |
• • – |
2019-02-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
73,947 |
414,703 |
|
- |
|
| Wolk Joseph J |
Exec VP, CFO |
• • – |
2019-02-11 |
4 |
D |
$131.94 |
$126,794 |
D/D |
(961) |
13,920 |
|
- |
|
606 Records found
|
|
Page 14 of 25 |
|
|
1.61 (1.05%) 
